Compare General Mills, Inc. (GIS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs ResMed Inc. — how do they compare? General Mills, Inc. trades at $32.07 (market cap $17.43B), while ResMed Inc. trades at $229.72 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and ResMed Inc. for 51 Days on average.
| GIS | RMD | |
|---|---|---|
Market Cap | $17.43B | $31.89B |
Volume | 16,554,362 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $277.88 |
52-Week Low | $31.67 | $182.82 |
Typical Hold Time | 106 Days | 51 Days |
Enterprise Value | $30.61B | $31.24B |
Dividend Yield | 7.49% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.77, down 1.27% with bearish technical signals despite beating Q2 2026 EPS estimates. The stock shows attractive valuation metrics with P/E of 9.23 and P/S of 0.96, but faces fundamental challenges including negative net income margin of -4.89% and declining revenue trends from $19.5B in 2025 to projected $18.3B in 2026. Recent CEO transition to Dana McNabb and dividend stability at $0.61 quarterly provide some stability amid operational headwinds.
The outlook remains cautious with Wall Street showing mixed sentiment - 61% hold ratings but $36 consensus target suggests 13% upside. Key risks include ongoing margin pressure, competitive threats in packaged foods, and macroeconomic sensitivity. The high 7% dividend yield offers income appeal but sustainability concerns persist given negative profitability metrics and cash flow challenges.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
